Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

Fig. 3

Proposed management strategy for hepatitis B surface antigen (HBsAg)-positive patients starting anti-PD-1-antibody-containing immunotherapy. (*) The optimal duration of prophylactic antiviral therapy after the discontinuation of anti-PD-1 therapy remains to be determined. Anti-PD-1, anti-programmed cell death 1; PD-L1, programmed cell death-ligand 1; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus

Back to article page